CSL Behring

Read more
Paul Perreault's photo - CEO of CSL Behring

CEO

Paul Perreault

CEO Approval Rating

97/100

Founded:

1904

Status:

PrivateSubsidiary of CSL Limited

Est. Annual Revenue
$9.1B
Est. Employees
27,000

CSL BEHRING TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Paul Perreault

CEO

- -
27,000
$0
$9.1B
View Profile
1

Jose E Almeida

Chairman & CEO

64/100
50,000
$1.8M
$12.2B
View Profile
2

Raimon Grifols Roura

Co-CEO

88/100
24,016
- -
$6.5B
View Profile
3

Wolfgang Marguerre

Chairman & CEO

70/100
9,067
- -
$2.9B
View Profile
4

Michael Amoroso

President & CEO

83/100
83
$13.9M
$10M
View Profile
5

Robert G. Kramer

President & CEO

85/100
1,705
$801.5M
$1.7B
View Profile
6

Russell H. Ellison

President & CEO

85/100
269
$86.7M
$61.8M
View Profile
7

Robert F Apple

President & CEO

89/100
165
$60.6M
$158.6M
View Profile
8

Adam S. Grossman

Founder & CEO

69/100
314
$21M
$48.1M
View Profile
9

CEO

- -
440
- -
$304.2M
View Profile
10

Daniel Peisert

CEO

- -
125
$618.8M
$112.2M
View Profile

Missing a competitor? Contribute!

Baxter is one of CSL Behring's top competitors. Baxter was founded in 1931, and its headquarters is in Deerfield, Illinois. Baxter competes in the Health Care Equipment field. Baxter has 23,000 more employees than CSL Behring.

Grifols is CSL Behring's #2 rival. Grifols was founded in 1909 in Barcelona, Barcelona. Grifols competes in the Health Care Equipment industry. Grifols generates $2.6B less revenue than CSL Behring.

Octapharma is a top competitor of CSL Behring. Octapharma is a Private company that was founded in Lachen, Schwyz in 1983. Octapharma operates in the Biotechnology industry. Octapharma has 17,933 fewer employees vs. CSL Behring.

CSL Behring Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Vitaeris, Inc.

Jun 2020

Source »
undisclosed
Vitaeris is a biopharmaceutical company that researches, develops and commercializes novel therapeutics for the treatment of rheumatoid arthritis.

These are all the companies that CSL Behring has acquired. CSL Behring's latest acquisition was Vitaeris, Inc. in Jun 2020. Vitaeris is a biopharmaceutical company that researches, develops and commercializes novel therapeutics for the treatment of rheumatoid arthritis.

CSL Behring Funding History

No recent funding data found related to CSL Behring

CSL Behring Investments

No recent investments found related to CSL Behring

CSL Behring News

May 1, 2021Pharmabiz

US FDA approves label update for CSL Behring's Hizentra to treat chronic inflammatory demyelinating polyneuropathy

CSL Behring, a global biotech company, announced that the US Food and Drug Administration (FDA) has a... See more »
March 24, 2021MarketScreener

and CSL Behring Announce the Finalists for the 2021 Transplant Innovation Challenge

(marketscreener.com) NEW YORK and KING OF PRUSSIA, Pa., March 24, 2021 /PRNewswire/ -- Lyfebulb, a pa... See more »
February 4, 2021FiercePharma

CSL Behring teams with Lyfebulb to create first online social community for transplant patients

CSL Behring teams with Lyfebulb to create first online social community for transplant patients sharo... See more »
January 25, 2021Markets Insider

Lyfebulb and CSL Behring Launch TransplantLyfe, a First-of-its-Kind Community Engagement Platform for Transplant Patients

NEW YORK, Jan. 25, 2021 /PRNewswire/ -- Global biotherapeutics leader CSL Behring, and patient empowe... See more »
January 22, 2021Pharmacy Business

CSL Behring recalls specific batches of Respreeza

CSL Behring UK Ltd has recalled specific batches of Respreeza 1,000 mg powder and solvent for solutio... See more »
November 19, 2020FierceBiotech

Gene therapy hemophilia B 'cure' approach heats up as uniQure/CSL, rivalling Pfizer, shows promise

Gene therapy hemophilia B 'cure' approach heats up as uniQure/CSL, rivalling Pfizer, shows promise ba... See more »
November 12, 2020Australian Manufacturing

CSL Starts Manufacturing a Potential COVID-19 Vaccine

CSL begins production in Australia of the vaccine candidate developed by the University of Oxford and... See more »

CSL Behring Blogs

August 24, 2017CSL Behring Blog

Putting Patients First: Why We Partner with Advocacy Groups

By Dr. Lutz Bonacker August 24, 2017 At CSL Behring we have been working collaboratively with patient... See more »
July 25, 2017CSL Behring Blog

Novel Ways of Using Immunoglobulin to Treat Disabling Neurological Disorders Are Being Explored

Researchers are targeting autoimmune epilepsy and chronic inflammatory demyelinating polyneuropathy. ... See more »
June 20, 2017CSL Behring Blog

Yesli's Story: Income Inequality, Mountainous Terrain and a Shortage of Specialists Hamper Diagnosis and Treatment of Rare Diseases in Chile

By Juan Ambar June 20, 2017 Yesli Jordán Paillacán overcame a childhood made difficult ... See more »
May 15, 2017CSL Behring Blog

The Rarity of Hereditary Angioedema Makes the Disease Especially Dangerous

That's why awareness opportunities such as HAE Day are so important. By Debra Bensen-Kennedy, MD May ... See more »
May 8, 2017CSL Behring Blog

Bugs May Be Regaining the Upper Hand Over Once Effective Antibiotics

Antibiotic resistance and rare diseases were among the topics explored by a panel of scientists and p... See more »
April 27, 2017CSL Behring Blog

The Challenges of Diagnosing, Treating and Finding a Cure for Primary Immunodeficiency - One Doctor's Perspective

More patients are being properly diagnosed and treated than ever before, but obstacles remain in the ... See more »
April 20, 2017CSL Behring Blog

Baylee’s Story

“It’s a miracle you’re still alive.” April 20, 2017 High school student and common variable immune de... See more »

CSL Behring Press Releases

November 5, 2020PR Newswire

CSL Behring Publishes Design for First-Ever Outcomes Study of ApoA-I to Reduce Risk of Cardiovascular Events in Heart Attack Patients

KING OF PRUSSIA, Pa., Nov. 5, 2020 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today an... See more »
November 2, 2020PR Newswire

Orphan Drug Designation Granted for CSL Behring's Investigational Plasma-Derived Hemopexin Therapy for Sickle Cell Disease

KING OF PRUSSIA, Pa., Nov. 2, 2020 /PRNewswire/ -- Global biotherapeutics leader CSL Behring announce... See more »
April 21, 2020PR Newswire

CSL Behring Announces Results from Three Analyses of Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) in Primary Immunodeficiency (PI)

PHILADELPHIA, April 21, 2020 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announce... See more »
April 8, 2020Korea Newswire

Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy

Biotest, BPL, LFB, and Octapharma have joined an alliance formed by CSL Behring (ASX:CSL/USOTC:CSLLY)... See more »
February 11, 2020centralcharts

PRIVIGEN® (Immune Globulin Intravenous (Human), 10% Liquid) Granted Orphan-Drug Designation for the Investigational Treatment of Systemic Sclerosis (SSc)

PRIVIGEN® (Immune Globulin Intravenous (Human), 10% Liquid) Granted Orphan-Drug Designation for the I... See more »
January 21, 2020PR Newswire

Forbes Magazine Ranks CSL Behring Among Best Employers for Diversity

KING OF PRUSSIA, Pa., Jan. 21, 2020 /PRNewswire/ -- Forbes Magazine today named CSL Behring among its... See more »
January 9, 2020StreetInsider

Global Biotech Leader CSL to Present at 38th Annual J.P. Morgan Healthcare Conference

KING OF PRUSSIA, Pa., Jan. 9, 2020 /PRNewswire/ --Â Global biotechnology giant CSL Limited, parent co... See more »

CSL Behring Videos

February 1, 2021CSL Behring Youtube Channel

"Hitting Her Mark: Machelle's Story" on YOUTUBE

February 1, 2021CSL Behring Youtube Channel

"Winning Access: Michael's Story" on YOUTUBE

February 1, 2021CSL Behring Youtube Channel

"How to Travel With Medication" on YOUTUBE

February 1, 2021CSL Behring Youtube Channel

"How to Find a Rare Disease Diagnosis" on YOUTUBE

Social Media

CSL Behring Headquarters

1020 First Avenue

King of Prussia, Pennsylvania19406-0901

1-610-878-4000

Driving Directions »

Trending Companies

CSL Behring Summary

ABOUT

Overview

CSL Behring manufactures and markets protein-based therapies for the treatment of bleeding disorders and pulmonary diseases. CSL Behring was founded in 1904. CSL Behring's headquarters is located in King of Prussia, Pennsylvania, USA 19406-0901. CSL B...

CEO

CSL Behring's CEO, Paul Perreault, currently has an approval rating of 97%. CSL Behring's primary competitors are Baxter, Grifols & Octapharma.

Frequently Asked Questions about CSL Behring

  1. When was CSL Behring founded?

    CSL Behring was founded in 1904
  2. Who is CSL Behring's CEO?

    CSL Behring's CEO is Paul Perreault
  3. How much revenue does CSL Behring generate?

    CSL Behring generates $9.1B in revenue
  4. How much funding does CSL Behring have?

    CSL Behring has historically raised $0 in funding
  1. Where is CSL Behring's headquarters?

    CSL Behring's headquarters is in King of Prussia Pennsylvania, USA
  2. How many employees does CSL Behring have?

    CSL Behring has 27,000 employees
  3. What sector does CSL Behring operate in?

    CSL Behring is in Pharmaceuticals
  4. Who are CSL Behring's competitors?

    CSL Behring's top competitors are Baxter, Grifols, Octapharma